Navigation Links
Medco to Webcast Annual Analyst Day Conference
Date:11/15/2007

FRANKLIN LAKES, N.J., Nov. 15 /PRNewswire-FirstCall/ -- Medco Health Solutions, Inc. (NYSE: MHS) Chairman and Chief Executive Officer David B. Snow Jr., and other members of his senior management team, will present an overview of the company's business, strategy and financial results to analysts and institutional investors during its annual Analyst Day conference on Friday, Nov. 16, 2007. The event, titled "Advancing the Practice of Pharmacy," is scheduled to begin at 8 a.m. EST.

Presentations and accompanying slides will be available via live webcast. To access the webcast, or the presentation slides, visit http://www.medco.com/investor.

About Medco

Medco Health Solutions, Inc., (NYSE: MHS) is the nation's leading pharmacy benefit manager based on its 2006 total net revenues of more than $42 billion. Medco's prescription drug benefit programs, covering one in five Americans, are designed to drive down the cost of pharmacy healthcare for private and public employers, health plans, labor unions and government agencies of all sizes, and for individuals served by the Medicare Part D Prescription Drug Program. Medco, the world's most advanced pharmacy(TM), has created Medco Therapeutic Resource Centers(TM) that are staffed with hundreds of specialist pharmacists who are trained and certified in specific chronic and complex conditions and have expertise in the associated medications. With the 2007 acquisition of Liberty Medical, Medco is the nation's largest diabetes pharmacy care practice based on covered lives. Medco is the largest specialty pharmacy based on net revenues with the 2005 acquisition of Accredo Health Group, Inc. Medco is also the highest-ranked independent pharmacy benefit manager on the 2007 Fortune 500 list. On the Net: http://www.medco.com.

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. We undertake no obligation to publicly update any forward- looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the risks and uncertainties that affect our business, particularly those mentioned in the Risk Factors section of the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission.


'/>"/>
SOURCE Medco Health Solutions, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion
2. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
3. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
4. Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation
5. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Volcano Corporation Presentation at Bear Stearns Conference to be Webcast
9. Telik Announces Presentation and Webcast at Bear Stearns Healthcare Conference
10. ZymoGenetics to Webcast Presentation at Two Upcoming Conferences
11. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... N.J. , May 4, 2016  Bayer ... its oncology compound Stivarga ® (regorafenib) tablets ... carcinoma (HCC) has met its primary endpoint of ... study, called RESORCE, evaluated the efficacy and safety ... has progressed after treatment with sorafenib. The safety ...
(Date:5/4/2016)... ... May 04, 2016 , ... Nutrafol®, a first-to-market ... treat hormonal and stress related hair loss. With patent-pending formulas for both female ... opinion leaders in the medical and salon channels nationwide. , Dermatologists, Plastic ...
(Date:5/3/2016)... ... May 03, 2016 , ... Leading CEOs from ... May 31st and June 1st at The Four Seasons Hotel Boston. , The ... life sciences, offering exclusive access to key decision makers who influence deal making ...
(Date:5/3/2016)... 3, 2016 - And Other ... Producers of Those Competitor Biologics  - Biosimilar ... and Prospects ,  Who are the most ... what are their sales potentials? Discover, in our updated ... trends, opportunities and revenue forecasting. Visiongain,s ...
Breaking Biology Technology:
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting ... are setting a new clinical standard in telehealth thanks ... By leveraging the higi platform, IMPOWER patients can routinely ... pulse and body mass index, and, when they opt ... and convenient visit to a local retail location at ...
(Date:3/23/2016)... 2016 Einzigartige ... und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler Kommunikationsdienste, ... SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie einzusetzen. ... Möglichkeit angeboten, im Rahmen mobiler Apps neben ...
(Date:3/18/2016)... --> --> Competitive Landscape ... Vehicles, Physical infrastructure and Perimeter Surveillance & Detection Systems ... market and the continuing migration crisis in the ... has led visiongain to publish this unique report, which is ... & security companies in the border security market and ...
Breaking Biology News(10 mins):